Business Context and Reporting Period
This Form 10-Q covers Eli Lilly & Co. for the quarterly period ended June 30, 1994, and the six-month period ended June 30, 1994. The company operates in pharmaceuticals, medical devices and diagnostics, and animal health. As of July 31, 1994, there were 292,100,954 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 1994 | Q2 1993 | 6M 1994 | 6M 1993 |
|---|---|---|---|---|
| Net Sales ($ millions) | 1,678.5 | 1,561.0 | 3,315.5 | 3,121.0 |
| Net Income ($ millions) | 346.6 | 346.8 | 677.3 | 709.4 |
| Earnings Per Share ($) | 1.20 | 1.18 | 2.34 | 2.42 |
| Operating Cash Flow ($ millions) | N/A | N/A | 487.3 | 497.3 |
| Total Debt ($ millions) | 1,849.6 | N/A | 1,849.6 | 1,360.0 |
| Cash & Short-term Investments ($ millions) | 1,275.4 | N/A | 1,275.4 | 987.1 |
| Cost of Sales Margin (%) | 31.2% | 30.1% | 31.4% | 29.4% |
Note: Total debt for 6M 1993 is calculated as Short-term borrowings ($524.8M) + Long-term debt ($835.2M) from the Dec 31, 1993 balance sheet. Q2 1994 operating cash flow is not explicitly stated for the quarter alone in the provided text, only for the six-month period.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% in Q2 1994 and 6% for the first six months compared to 1993. Growth was driven by an 11% volume increase, partially offset by a 3% price decrease in Q2.
- Profitability: Net income remained flat in Q2 1994 compared to Q2 1993 but declined 5% for the first six months. This decline was primarily due to a $66 million pre-tax special charge related to a voluntary recall of liquid oral antibiotics.
- Cost Structure: Cost of sales as a percentage of sales increased to 31.2% in Q2 and 31.4% for the six months, up from 30.1% and 29.4% respectively in 1993. Management attributes this to reduced annual production requirements to lower inventory levels.
- Debt Levels: Total debt increased by $489.6 million to $1,849.6 million as of June 30, 1994, compared to December 31, 1993.
Guidance, Outlook, and Risks
- Acquisitions: In July 1994, the company announced a definitive agreement to acquire PCS Health Systems, Inc. for $4 billion in cash, to be financed by new debt. Additionally, an agreement was signed to acquire Sphinx Pharmaceuticals for approximately $80 million.
- Divestitures: The company announced the formation of Guidant Corporation, a new publicly owned entity comprising five of its Medical Devices and Diagnostics businesses. Physio-Control Corporation was sold to Bain Capital in July 1994.
- Legal and Contingencies: The company faces product liability lawsuits regarding diethylstilbestrol and Prozac, as well as patent litigation and environmental cleanup costs (Superfund). Total gross liabilities for these matters were approximately $492 million at June 30, 1994, with estimated insurance recoverables of $168 million.
- Rating Review: Following the PCS acquisition announcement, Standard & Poor's and Moody's placed the company's long-term debt ratings under review for possible downgrade.
- Outlook: Management expects the higher cost of sales percentage to continue throughout the year.
Investor Verification Checklist
- Verify the final regulatory approval and closing date of the $4 billion PCS Health Systems acquisition.
- Monitor the status of credit rating reviews by S&P and Moody's following the increased debt load.
- Track the resolution of product liability lawsuits involving Prozac and diethylstilbestrol to assess potential changes in accrued liabilities.
- Confirm the timeline and terms of the Guidant Corporation spin-off and IPO.
- Review future quarters for the persistence of elevated cost of sales margins due to production adjustments.